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Background: Atrial fibrillation (AF) and heart failure (HF) are highly prevalent conditions that often coexist. The associated financial burden is 
tremendous. In the AF-CHF trial that compared rhythm vs rate control strategies in symptomatic patients with HF and AF, no differences were found 
in primary and secondary efficacy end-points, including cardiovascular death. The objective of this study was to determine whether cost analyses 
favoured one approach over the other.
Methods: All AF-CHF patients from Quebec were analyzed from a single-payer perspective. The temporal horizon was limited to in-trial patient-
specific resource utilization including hospitalisations, cardiovascular (CV) procedures, emergency room visits (ER), all other ambulatory encounters, 
and medications. Data was derived from the physician’s services and claims database and the pharmaceutical database from the Régie de 
l’assurance-maladie du Québec (RAMQ). Disease specific per diem costs of hospitalizations and procedures were estimated from the Ontario Case 
Costing Initiative. ER costs were based on data from the Montreal Heart Institute. All costs were expressed in 2009 Canadian dollars.
Results: A total of 304 patients were included. Patients assigned to rate control were hospitalized for longer periods (33.6 vs 29.6 days 
per patient, P=0.36). CV procedures were less frequent in the rate control group (146 vs 238), predominantly driven by a higher number of 
cardioversions. Defibrillators and biventricular pacemakers were more commonly implanted in the rate control group. Pharmaceutical expenditures 
were similar ($9,681 vs $10,308 per patient, P=0.55). ER and other ambulatory encounters were likewise similar. Overall, the mean total medical 
cost per patient during the AF-CHF trial was estimated to be $78,767 with rate control group and $72,764 with rhythm control (p=0.49).
Conclusions: The overall financial burden is similar with rhythm versus rate control strategies in patients with AF and HF. Despite the added cost 
of therapy needed to maintain sinus rhythm in the rhythm control group, this was counterbalanced by increased costs for hospitalisations in the rate 
control group.
